Antibody-Drug Conjugates: New Frontier in Cancer Therapeutics

Handbook of Therapeutic Antibodies: Second Edition

Volumn 1-4, Issue , 2014, Pages 341-362

  Singh, Rajeeva ^a   Lambert, John M ^a   Chari, Ravi V J ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

ADC; Antibody; Conjugate; Drug; Linker; Maytansinoid

Indexed keywords

ANTIBODIES; MONOCLONAL ANTIBODIES;

ANTIBODY-DRUG CONJUGATES; CANCER THERAPEUTICS; CONJUGATE; CYTOTOXIC AGENTS; DRUG; LINKER; MAYTANSINOID; RESEARCH INITIATIVES;

DISEASES;

EID: 84930628046     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527682423.ch13     Document Type: Chapter

References (62)

1. Teicher, B.A. and Chari, R.V. (2011) Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res., 17 (20), 6389-6397.
2. Lambert, J.M. et al. (1991) An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res., 51 (23, Pt. 1), 6236-6242.
3. Becker, N. and Benhar, I. (2012) Antibody-based immunotoxins for the treatment of cancer. Antibodies, 1 (1), 39-69.
4. Kreitman, R.J. and Pastan, I. (2011) Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin. Cancer Res., 17 (20), 6398-6405.
5. Kreitman, R.J. et al. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol., 30 (15), 1822-1828.
6. Kreitman, R.J. (2006) Immunotoxins for targeted cancer therapy. AAPS J., 8 (3), E532-E551.
7. Singh, R. and Erickson, H.K. (2009) Antibody-cytotoxic agent conjugates:preparation and characterization. Methods Mol. Biol., 525, 445-467, xiv.
8. Hong, W.K. and American Association for Cancer Research (2010) Holland Frei Cancer Medicine 8, 8th edn, People's Medical Publishing House, Shelton, CT, p. xxv, 2,021 p.
9. Vogelstein, B. et al. (2013) Cancer genome landscapes. Science, 339 (6127), 1546-1558.
10. Abbas, A.K., Lichtman, A.H., and Pillai, S. (2012) Cellular and Molecular Immunology, 7th edn, Elsevier/Saunders, Philadelphia, PA, p. x, 545 p.
11. Scott, A.M., Wolchok, J.D., and Old, L.J. (2012) Antibody therapy of cancer. Nat. Rev. Cancer, 12 (4), 278-287.
12. Burris, H.A. 3rd, et al. (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol., 29 (4), 398-405.
13. Verma, S. et al. (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med., 367 (19), 1783-1791.
14. Sutherland, M.S. et al. (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem., 281 (15), 10540-10547.
15. Okeley, N.M. et al. (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin. Cancer Res., 16 (3), 888-897.
16. Ansell, S.M. et al. (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J. Clin. Oncol., 25 (19), 2764-2769.
17. Katz, J., Janik, J.E., and Younes, A. (2011) Brentuximab vedotin (SGN-35). Clin. Cancer Res., 17 (20), 6428-6436.
18. Younes, A. et al. (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol., 30 (18), 2183-2189.
19. Erickson, H.K. et al. (2012) The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol. Cancer Ther., 11 (5), 1133-1142.
20. Petersdorf, S.H. et al. (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood, 121 (24), 4854-4860.
21. Rowe, J.M. and Lowenberg, B. (2013) Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood, 121 (24), 4838-4841.
22. Perez, E.A. et al. (2005) Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest. New Drugs, 23 (3), 257-261.
23. Chabner, B.A. et al. (1978) Initial clinical trials of maytansine, an antitumor plant alkaloid. Cancer Treat. Rep., 62 (3), 429-433.
24. Rosenthal, S. et al. (1980) Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study. Cancer Treat. Rep., 64 (10-11), 1115-1117.
25. Chari, R.V. et al. (1992) Immunoconjugates containing novel maytansinoids:promising anticancer drugs. Cancer Res., 52 (1), 127-131.
26. Widdison, W.C. et al. (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem., 49 (14), 4392-4408.
27. Al-Katib, A.M. et al. (2009) Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin. Cancer Res., 15 (12), 4038-4045.
28. Blanc, V. et al. (2011) SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin. Cancer Res., 17 (20), 6448-6458.
29. Kellogg, B.A. et al. (2011) Disulfidelinked antibody-maytansinoid conjugates:optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjugate Chem., 22 (4), 717-727.
30. Erickson, H.K. et al. (2006) Antibodymaytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res., 66 (8), 4426-4433.
31. Doronina, S.O. et al. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol., 21 (7), 778-784.
32. Francisco, J.A. et al. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood, 102 (4), 1458-1465.
33. Doronina, S.O. et al. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery:effects of linker technology on efficacy and toxicity. Bioconjugate Chem., 17 (1), 114-124.
34. Verdier-Pinard, P. et al. (2000) Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity. Mol. Pharmacol., 57 (1), 180-187.
35. Dubowchik, G.M. et al. (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigenspecific in vitro anticancer activity. Bioconjugate Chem., 13 (4), 855-869.
36. King, H.D. et al. (2002) Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. J. Med. Chem., 45 (19), 4336-4343.
37. Hamblett, K.J. et al. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res., 10 (20), 7063-7070.
38. Oflazoglu, E. et al. (2008) Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin. Cancer Res., 14 (19), 6171-6180.
39. Zein, N. et al. (1988) Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science, 240 (4856), 1198-1201.
40. DiJoseph, J.F. et al. (2004) Antibodytargeted chemotherapy with CMC-544:a CD22-targeted immunoconjugate of calicheamicin for the treatment of Blymphoid malignancies. Blood, 103 (5), 1807-1814.
41. Advani, A. et al. (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J. Clin. Oncol., 28 (12), 2085-2093.
42. Sapra, P. et al. (2005) Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin. Cancer Res., 11 (14), 5257-5264.
43. Govindan, S.V. et al. (2009) CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin. Cancer Res., 15 (19), 6052-6061.
44. Steffens, M.G. et al. (1997) Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J. Clin. Oncol., 15 (4), 1529-1537.
45. Lewis Phillips, G.D. et al. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res., 68 (22), 9280-9290.
46. Girish, S. et al. (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother. Pharmacol., 69 (5), 1229-1240.
47. Kovtun, Y.V. et al. (2006) Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res., 66 (6), 3214-3221.
48. Erickson, H.K. et al. (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjugate Chem., 21 (1), 84-92.
49. Zhao, R.Y. et al. (2011) Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J. Med. Chem., 54 (10), 3606-3623.
50. Sun, X. et al. (2011) Design of antibodymaytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjugate Chem., 22 (4), 728-735.
51. Younes, A. et al. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med., 363 (19), 1812-1821.
52. Lazar, A.C. et al. (2005) Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun. Mass Spectrom., 19 (13), 1806-1814.
53. Wakankar, A. et al. (2011) Analytical methods for physicochemical characterization of antibody drug conjugates. mAbs, 3 (2), 161-172.
54. Junutula, J.R. et al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol., 26 (8), 925-932.
55. Stimmel, J.B. et al. (2000) Site-specific conjugation on serine right-arrow cysteine variant monoclonal antibodies. J. Biol. Chem., 275 (39), 30445-30450.
56. Shen, B.Q. et al. (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol., 30 (2), 184-189.
57. Axup, J.Y. et al. (2012) Synthesis of sitespecific antibody-drug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. U.S.A., 109 (40), 16101-16106.
58. Strop, P. et al. (2013) Location matters:site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol., 20 (2), 161-167.
59. Mohlmann, S. et al. (2011) Site-specific modification of ED-B-targeting antibody using intein-fusion technology. BMC Biotechnol., 11, 76.
60. Casi, G. et al. (2012) Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. J. Am. Chem. Soc., 134 (13), 5887-5892.
61. Natsume, A., Niwa, R., and Satoh, M. (2009) Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des. Dev. Ther., 3, 7-16.
62. Kim, K.M. et al. (2008) Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol. Cancer Ther., 7 (8), 2486-2497.